Upcoming Conferences
May 29, 2020
Geneos will be attending the following upcoming conferences:
- SITC, Nov. 2020, FL
- Neoantigen Summit, Nov. 2020, MA
Investor + Media Resources
Upcoming Conferences
GT-30: cGMP Manufacturing of First Clinical Lot
May 18, 2020
VGXI Enables Rapid GMP DNA Manufacturing Timeline for Geneos Therapeutics Personalized Cancer Immunotherapy
View PDF
Hepatocellular Carcinoma Trial
February 3, 2020
Geneos Personalized Neoantigen-Targeting Vaccine (GNOS-PV02) to be Utilized in Innovative GT-30 Hepatocellular Carcinoma Trial
View PDF
Lyfebulb-Helsinn Cancer Innovation Summit & Award
January 30, 2020
Geneos Therapeutics Named One of 11 Finalists for the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award. Niranjan Y. Sardesai, CEO of Geneos, presented at the Lyfebulb Helsinn Cancer Innovation Summit on January 30th, 2020 in Monaco.
Establish Supply Agreement
July 19, 2019
Texas Based CMO VGXI and Geneos Therapeutics Establish Supply Agreement for Production of GT- EPIC-Based Personalized Cancer Therapeutics
View PDF
Announcing First Patient Dosed
July 10, 2019
Geneos Therapeutics Announces First Patient Dosed
with its DNA-based, Neoantigen-Targeting Personalized Vaccine Technology
View PDF
Anticancer Immunity
February 24, 2019
Induction of Potent Anticancer Immunity Through Rapid Tumor Antigen Identification and Conversion to Personalized Synthetic DNA Vaccines
View PDF
Next Gen Neoantigen-Targeting Immunotherapies
February 21, 2019
Geneos Therapeutics Secures $10.5 Million in Series A Financing to Develop the Next Generation of Neoantigen-Targeting Cancer Immunotherapies
View PDF